Biotech Values

[DewDiligence]

EMEA Assessing Tysabri PML Cases

[The EU accounts for 40-45% of current Tysabri sales.]

http://www.reuters.com/article/marketsNews/idINLD44617020080813

›Wed Aug 13, 2008 11:32am EDT

LONDON, Aug 13 (Reuters) - The European Medicines Agency said on Wednesday it was assessing two cases of a potentially deadly brain disease reported last month in multiple sclerosis (MS) patients being treated with the drug Tysabri.

The London-based agency said it would then decide whether any changes were necessary to the currently approved label for product, which is made by Elan Corp Plc (ELN) and Biogen Idec Inc (BIIB).

Shares in both companies slumped following the July 31 news of the latest cases of the brain infection known as progressive multifocal leukoencephalopathy (PML).‹